Typed states for the displayed outbound observations.
Source: paper_references, paper_reference_links, observed 2026-08-14T12:34:29.224850Z
Paper Citation Record · LEDGER
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group
As of 16 August 2026, this Paper Citation Record lists 51 of 51 outbound references and 0 inbound Pith citation observations for arXiv:1908.07112.
A citation records a reference. It does not transfer a finding from one paper to another.
Coverage vector
One-hop event checks from named stored sources.
Source: scholarly_work_events, retraction_status_cache, observed 2026-08-16T06:30:59.297886+00:00
Pith citing papers itemized under the disclosed page cap.
Source: paper_references, paper_reference_links
A source-named dated measurement, never combined with another source.
Source: cited_works
Reference resolution
51 of 51 outbound references displayed
- verified exact0
- verified fuzzy44
- unresolved7
- parse uncertain0
- malformed identifier0
- metadata mismatch0
External citation measurements
No source-named external measurement is stored.
Outbound references
Observation 8108a581-ae81-41b5-baba-8f1cac163010 · outbound
This paper cites Nonparametric estimation from incomplete observations.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Nonparametric estimation from incomplete observations
Reference 1
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:30.196939Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 86906ec5-d65c-4e57-baf4-b2d32a34d61b · outbound
This paper cites Asymptotically efficient rank invariant test procedures.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Asymptotically efficient rank invariant test procedures
Reference 2
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:30.181055Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 6e5398b2-a499-438b-9b80-10f4293135c2 · outbound
This paper cites Regression models and life-tables.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Regression models and life-tables
Reference 3
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:30.165968Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 366d00f5-12d8-4ffe-ab4d-ffb3f1f25243 · outbound
This paper cites Statistical issues and challenges in immuno-oncology.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Statistical issues and challenges in immuno-oncology
Reference 4
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:30.150661Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 59e49fb8-cad1-4d8b-a42e-aa9eb7e6c289 · outbound
This paper cites an unresolved cited work.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Unresolved cited work
Reference 5
- Resolution
- unresolved
- raw_fallback, observed 2026-08-14T12:34:30.135333Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 0a16237a-b114-45ae-ac02-a4b2d22c07a7 · outbound
This paper cites Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer
Reference 6
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:30.120035Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation aab611ee-9c64-476a-ad1e-b01be58d12ac · outbound
This paper cites Pembrolizumab versus docetaxel for previously treated, pd-l1-positive, advanced non-small-cell lung cancer ( KEYNOTE-010 ): a randomised controlled trial.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Pembrolizumab versus docetaxel for previously treated, pd-l1-positive, advanced non-small-cell lung cancer ( KEYNOTE-010 ): a randomised controlled trial
Reference 7
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:30.102792Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 38fad69d-9560-4c0c-bf81-d7d33e407abf · outbound
This paper cites A class of rank test procedures for censored survival data.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group A class of rank test procedures for censored survival data
Reference 8
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:30.085658Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 63ccf99d-5cd8-4e37-a2a2-8eab12ccfe57 · outbound
This paper cites Cox analysis of survival data with non-proportional hazard functions.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Cox analysis of survival data with non-proportional hazard functions
Reference 9
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:30.068705Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 21dec4c6-0c46-4167-9b1b-ef569db6bde3 · outbound
This paper cites Designing therapeutic cancer vaccine trials with delayed treatment effect.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Designing therapeutic cancer vaccine trials with delayed treatment effect
Reference 10
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:30.051651Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation d992c7e0-50f2-4589-90f2-f1928c141e17 · outbound
This paper cites Designing cancer immunotherapy trials with random treatment time-lag effect.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Designing cancer immunotherapy trials with random treatment time-lag effect
Reference 11
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:30.033972Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation f4fd1f2b-b71f-4b11-86df-8b2fe6214a2f · outbound
This paper cites Modestly weighted logrank tests.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Modestly weighted logrank tests
Reference 12
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.890359Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation d1184a15-4928-42db-8ed2-4e7c795cfa0b · outbound
This paper cites Analyzing survival curves at a fixed point in time.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Analyzing survival curves at a fixed point in time
Reference 13
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.874692Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation cacd3e23-4414-4ab6-9006-249c11093e77 · outbound
This paper cites The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt
Reference 14
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.858829Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 8f788bda-f256-44a9-9a88-126d608ec85d · outbound
This paper cites Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis
Reference 15
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.842872Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 6fc519f0-57cb-4541-8793-9039e7fbe724 · outbound
This paper cites Predicting the restricted mean event time with the subject's baseline covariates in survival analysis.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Predicting the restricted mean event time with the subject's baseline covariates in survival analysis
Reference 16
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.827294Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 9565b3df-8df9-4814-9c30-a019c62e20e3 · outbound
This paper cites Weighted kaplan-meier statistics: A class of distance tests for censored survival data.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Weighted kaplan-meier statistics: A class of distance tests for censored survival data
Reference 17
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.812187Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation c19e0c91-d340-48f4-9648-f139470f7601 · outbound
This paper cites Alternative analysis methods for time to event endpoints under nonproportional hazards: A comparative analysis.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Alternative analysis methods for time to event endpoints under nonproportional hazards: A comparative analysis
Reference 18
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.795008Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation fd0f947b-7e96-43e1-b3a3-113d6104d4db · outbound
This paper cites Long-term survival with non-proportional hazards: results from the Dutch gastric cancer trial.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Long-term survival with non-proportional hazards: results from the Dutch gastric cancer trial
Reference 19
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.779626Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation e710538f-8206-4e3b-983c-7b3fe3d6f568 · outbound
This paper cites Testing treatment effect in randomized clinical trials with possible nonproportional hazards.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Testing treatment effect in randomized clinical trials with possible nonproportional hazards
Reference 20
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.763891Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation b81c3c66-99da-4de4-9a1f-44f1fe714879 · outbound
This paper cites On the versatility of the combination of the weighted log-rank statistics.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group On the versatility of the combination of the weighted log-rank statistics
Reference 21
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.747800Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 3808b5c6-b0ef-4212-b824-beefbe9cf9ce · outbound
This paper cites Some versatile tests based on the simultaneous use of weighted logrank and weighted kaplan-meier statistics.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Some versatile tests based on the simultaneous use of weighted logrank and weighted kaplan-meier statistics
Reference 22
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.732281Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation d0a29af6-6e45-40e0-9274-f003558aff40 · outbound
This paper cites A two-sample censored-data rank test for acceleration.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group A two-sample censored-data rank test for acceleration
Reference 23
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.715967Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation c901aefe-a061-4a4f-9c54-4f5726aad484 · outbound
This paper cites Some versatile tests based on the simultaneous use of weighted log-rank statistics.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Some versatile tests based on the simultaneous use of weighted log-rank statistics
Reference 24
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.700197Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 45d2bdad-941b-4307-b4ed-ddcc53a86dbb · outbound
This paper cites Comparing treatments in the presence of crossing survival curves: An application to bone marrow transplantation.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Comparing treatments in the presence of crossing survival curves: An application to bone marrow transplantation
Reference 25
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.685075Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 3deb350f-1448-491b-bd14-7bf446efb333 · outbound
This paper cites Improved logrank-type tests for survival data using adaptive weights.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Improved logrank-type tests for survival data using adaptive weights
Reference 26
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.669503Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 7c79a9be-d451-4650-8253-335cae778e2c · outbound
This paper cites Versatile tests for comparing survival curves based on weighted log-rank statistics.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Versatile tests for comparing survival curves based on weighted log-rank statistics
Reference 27
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.654138Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation b1b1965f-79b4-4855-8c51-7e7ea86e1810 · outbound
This paper cites Linear regression with censored data.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Linear regression with censored data
Reference 28
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.638567Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation c6ca4f57-25f9-40d6-915a-01b2865fcad8 · outbound
This paper cites Linear rank tests with right censored data.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Linear rank tests with right censored data
Reference 29
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.623270Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation b2dd6b34-5667-4701-b4c1-1df148f44ce0 · outbound
This paper cites Innovative estimation of survival using log-normal survival modelling on accent database.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Innovative estimation of survival using log-normal survival modelling on accent database
Reference 30
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.608384Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 8ef78264-cbab-4793-84d5-f61ec43fe8a8 · outbound
This paper cites Generalized pairwise comparisons of prioritized outcomes in the two-sample problem.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Generalized pairwise comparisons of prioritized outcomes in the two-sample problem
Reference 31
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.592997Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 902909d2-c574-4088-8a31-83ab92c9b3e3 · outbound
This paper cites an unresolved cited work.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Unresolved cited work
Reference 32
- Resolution
- unresolved
- raw_fallback, observed 2026-08-14T12:34:29.578279Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 379e33fc-adb8-41b7-979d-411111047e53 · outbound
This paper cites an unresolved cited work.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Unresolved cited work
Reference 33
- Resolution
- unresolved
- raw_fallback, observed 2026-08-14T12:34:29.562028Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 1cd8d44b-e496-4c97-acfc-270e29b01e48 · outbound
This paper cites Journal of Computational and Graphical Statistics 1992; 1(2): 141--149.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Journal of Computational and Graphical Statistics 1992; 1(2): 141--149
Reference 34
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.545658Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation fe7cdcbd-b195-4a0c-b365-695e892a54fa · outbound
This paper cites Methods for accommodating nonproportional hazards in clinical trials: Ready for the primary analysis? Journal of Clinical Oncology 2019; 37(35): 3455--3459.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Methods for accommodating nonproportional hazards in clinical trials: Ready for the primary analysis? Journal of Clinical Oncology 2019; 37(35): 3455--3459
Reference 35
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.530003Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 2d227bd6-eca2-4ecb-a006-ab85d355a25b · outbound
This paper cites Monitoring for lack of benefit: A critical component of a randomized clinical trial.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Monitoring for lack of benefit: A critical component of a randomized clinical trial
Reference 36
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.514262Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 14e2c214-b338-4c20-a921-5ccd8651049a · outbound
This paper cites The consequences of proportional hazards based model selection.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group The consequences of proportional hazards based model selection
Reference 37
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.498658Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 57001ebd-d1e5-4dcd-8ccf-7b04518badff · outbound
This paper cites Proportional hazards tests and diagnostics based on weighted residuals.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Proportional hazards tests and diagnostics based on weighted residuals
Reference 38
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.483961Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 20864a17-01ac-43c3-b010-2ba8d7a6890b · outbound
This paper cites The estimation of average hazard ratios by weighted cox regression.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group The estimation of average hazard ratios by weighted cox regression
Reference 39
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.468832Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 1d0d7606-21d6-415a-8972-63159d902198 · outbound
This paper cites Estimating average regression effect under non-proportional hazards.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Estimating average regression effect under non-proportional hazards
Reference 40
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.452787Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation a3e59004-fd59-4ce3-931c-0c4193aac1ba · outbound
This paper cites an unresolved cited work.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Unresolved cited work
Reference 41
- Resolution
- unresolved
- raw_fallback, observed 2026-08-14T12:34:29.435453Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation c5421182-533d-490f-8f3e-10dd2fe2488d · outbound
This paper cites Enhanced secondary analysis of survival data: reconstructing the data from published kaplan-meier survival curves.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Enhanced secondary analysis of survival data: reconstructing the data from published kaplan-meier survival curves
Reference 42
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.417834Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 7544c108-8bfb-49df-9a1e-23f6ca7529f0 · outbound
This paper cites an unresolved cited work.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Unresolved cited work
Reference 43
- Resolution
- unresolved
- raw_fallback, observed 2026-08-14T12:34:29.401419Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 3aaa76e4-64ea-41b8-9530-2d42757715d7 · outbound
This paper cites an unresolved cited work.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Unresolved cited work
Reference 44
- Resolution
- unresolved
- raw_fallback, observed 2026-08-14T12:34:29.384304Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation f7749ae5-5540-4d95-8293-a16f372c1c63 · outbound
This paper cites Group sequential tests for long-term survival comparisons.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Group sequential tests for long-term survival comparisons
Reference 45
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.368438Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 7e7cc105-e155-47ba-ad7c-b01d921d2cf0 · outbound
This paper cites Sample size determination for the weighted log-rank test with the fleming–harrington class of weights in cancer vaccine studies.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Sample size determination for the weighted log-rank test with the fleming–harrington class of weights in cancer vaccine studies
Reference 46
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.350578Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 45d39089-6b05-420e-9716-6b8f88db46d8 · outbound
This paper cites Group sequential monitoring based on the weighted log-rank test statistic with the fleming–harrington class of weights in cancer vaccine studies.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Group sequential monitoring based on the weighted log-rank test statistic with the fleming–harrington class of weights in cancer vaccine studies
Reference 47
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.332104Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 19ecf86f-3c92-4261-8544-a764ca5aa17c · outbound
This paper cites Repeated significance testing for a general class of statistics used in censored survival analysis.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Repeated significance testing for a general class of statistics used in censored survival analysis
Reference 48
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.315966Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation a5630240-8882-4190-998a-884cd892c4fc · outbound
This paper cites Interim analysis: The alpha spending function approach.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Interim analysis: The alpha spending function approach
Reference 49
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.298975Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation 3057f472-a5fa-49c9-b8c2-bfd384cc6085 · outbound
This paper cites an unresolved cited work.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Unresolved cited work
Reference 50
- Resolution
- unresolved
- raw_fallback, observed 2026-08-14T12:34:29.282760Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Observation a004391f-da67-4ae4-b3de-b0d3c099b1cd · outbound
This paper cites Modeling Survival Data: Extending the C ox Model.
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group Modeling Survival Data: Extending the C ox Model
Reference 51
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-14T12:34:29.266264Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.
Pith citing papers
No inbound Pith citation observations are available.